RxDoctor Payments Data

Sunny Srivastava, MD

Cardiovascular Disease · Haverhill, MANPI 1083693360

Payments from drug & device makers

What this record shows

That places this record below the midpoint for cardiovascular disease clinicians in MA, where the typical reported total is $954.

$28in general payments, 2019–2025

Across 2 payments — averaging $13.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$14
  • Novartis$14
$1,185,371in research payments, 2019–2025

Across 102 payments — averaging $11,621 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$613K
  • Amgen$514K
  • AstraZeneca$32K
  • Pfizer$22K
  • Bayer$3K
  • Novo Nordisk AS$1K

What the payments were for

  • Food & beverage$1450%
  • Education$1450%

General payments by program year

22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$14
Novartis1$14

How this compares

$28 in reported general payments places this provider in the 5th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$519,465
Medicare patients
1,976
Services billed
8,089

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban807$983,077
XareltoRivaroxaban252$344,985
FarxigaDapagliflozin Propanediol110$144,102
EntrestoSacubitril/Valsartan89$115,903
JardianceEmpagliflozin39$38,100
Repatha SureclickEvolocumab16$24,218
Metoprolol Succinate895$18,362
BrilintaTicagrelor15$16,408
Atorvastatin Calcium649$9,841
Rosuvastatin Calcium307$9,431
Diltiazem 24hr Er (Cd)Diltiazem Hcl181$6,436
Ezetimibe114$5,191
Warfarin Sodium242$3,354
Amlodipine Besylate335$3,097
Furosemide425$2,724

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$14$160,509125 claims
NovartisEntresto$14$115,90389 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Haverhill

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →